Interní Med. 2009; 11(1): 7-14

Kombinovaná hypolipidemická léčba u pacientů

prof. MUDr. Vladimír Bláha CSc
Klinika gerontologická a metabolická, FN Hradec Králové

Monotherapy with statins is frequently a very successful strategy to reach target plasma levels of LDL (low density lipoprotein) cholesterol

(LDL-C) nevertheless in patients with mixed dyslipidemy and high cardiovascular risk which are typical for patients with metabolic

syndrome and type 2 diabetes mellitus may not lead this therapy to target levels for compensation of dyslipidemy. To reach treatment

goals it is necessary to use double or triple combination and hypolipidemics that can simultaneously influence complex abnormalities

of lipid profile. The most frequently used option is combination of a statin with fenofibrate or niacine (nicotinic acid); suitable is also

a combination with omega-3 fatty acids or ezetimib. On combined treatment with hypolipidemics a careful monitoring of patients because

of an increased risk of adverse effects and drug interactions is necessary.

Keywords: Key words: dyslipidemia, cardiovascular risk, atherosclerosis, metabolic syndrome, diabetes mellitus type 2, hypolipidemic therapy.

Published: March 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bláha V. Kombinovaná hypolipidemická léčba u pacientů. Interní Med. 2009;11(1):7-14.
Download citation

References

  1. Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol 2004; 94: 935-938. Go to original source... Go to PubMed...
  2. Assmann G, Cullen P, Schulte H. The Munster Heart study (PRO-CAM). Results of follow-up at 8 years. Eur Heart J 1998; 19 (Suppl. A): A2-11. Go to original source... Go to PubMed...
  3. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002; 25: 1198-202. Go to original source... Go to PubMed...
  4. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997; 80: 608-613. Go to original source... Go to PubMed...
  5. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81 (4A): 7B-12B. Go to original source... Go to PubMed...
  6. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68: 122-129. Go to original source... Go to PubMed...
  7. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampicin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 2005; 78: 154-167. Go to original source... Go to PubMed...
  8. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278. Go to original source... Go to PubMed...
  9. Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005; 149: 464-473. Go to original source... Go to PubMed...
  10. Ballantyne CM, Weiss R, Moccetti T et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007; 99: 673-680. Go to original source... Go to PubMed...
  11. Bansal S, Buring JE, Rifai N et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 297: 309-316. Go to original source... Go to PubMed...
  12. Bergman AJ, Murphy G, Burke J et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004; 44: 1054-1062. Go to original source... Go to PubMed...
  13. Brown BG, Brockenbrough A, Zhao XQ, et al. Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: a 10-year Familial Atherosclerosis Treatment Study (FATS) follow-up. Circulation 1998; 98: 1-635.
  14. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-1592. Go to original source... Go to PubMed...
  15. Bultas J. Kombinační léčba dyslipidémií. Interní Med. 2006 (7, 8): 314-322.
  16. Buse JB, Bigger JT, Byington RP, et al. Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99: 21i-33i. Go to original source... Go to PubMed...
  17. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504. Go to original source... Go to PubMed...
  18. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405-418. Go to original source... Go to PubMed...
  19. Cefali EA, Simmons PD, Stanek EJ, Shamp TR. Improved control of niacin-induced flushing using an optimized oncedaily, extended-release niacin formulation. Int J Clin Pharm Ther 2006; 44: 633-640. Go to original source... Go to PubMed...
  20. Clinical Trial: AIM HIGH. Niacin plus statin to prevent vascular events. [WWW document]. URL http://www.clinicaltrials.gov.ct/show/NCT00120289 [accessed on 24 April 2007].
  21. Češka R. Kombinace statin a fibrát v léčbě dyslipidemie.
  22. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007; 99 (Suppl.): 3C-18C. Go to original source... Go to PubMed...
  23. Deedwania P, Barter P, Carmena R et al. Reduction of lowdensity lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006; 368: 919-928. Go to original source... Go to PubMed...
  24. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISS-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infartio miocardico. Lancet 1999; 354: 447-455.
  25. Durrington PN, Bhatnager D, Mackness MI et al. An omega-3-polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001; 85: 544-548. Go to original source... Go to PubMed...
  26. Feher MD, Caslake M, Foxton J, Cox A, Packard CJ. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev 1999; 15: 395-399. Go to original source... Go to PubMed...
  27. Goldberg A, Alagona P Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of nicotinic acid in the management of hyperlipidemia. Am J Cardiol 2000; 85: 1100-5. (a) Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-81. (b) Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-1255. Go to original source... Go to PubMed...
  28. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15. Go to original source... Go to PubMed...
  29. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High-density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-714. Go to original source... Go to PubMed...
  30. Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med 2002; 162: 1568-1576. Go to original source... Go to PubMed...
  31. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005; 95: 462-468. Go to original source... Go to PubMed...
  32. Gustavson LE, Schweitzer SM, Koehne-Voss S et al. The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3?-hydroxy isomeric metabolite. J Clin Pharmacol 2005; 45: 947-53. Go to original source... Go to PubMed...
  33. Harris WS, Connor WE, Allam N, Illingworon DR. Reduction of postprandial triglyceridemia in humans by dietary n-3 fatty acids. J Lipid Res 1988; 29: 1451-1460. Go to original source...
  34. Harris WS. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997; 65 (5 Suppl.): 1645S-1654S. Go to original source... Go to PubMed...
  35. Harris WS. Omega-3 fatty acids and cardiovascular disease: a case for omega-3 index as a new risk factor. Pharmacol Res 2007; 55: 217-223. Go to original source... Go to PubMed...
  36. Hopkins PN, Heiss G, Ellison RC, et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation 2003; 108: 519-523. Go to original source... Go to PubMed...
  37. Chan DC, Watts GF, Barrett PH, Berlin LJ, Redgrave TG, Mori TA. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulinresistant obese male subjects with dyslipidemia. Diabetes 2002; 51: 2377-2386. Go to original source... Go to PubMed...
  38. Chan DC, Watts GF, Nguyen MN, Barrett PH. Factorial study of the effect of w-3-fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. Am J Clin Nutr 2006; 84: 37-43. Go to original source... Go to PubMed...
  39. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003; 171: 1-13. Go to original source... Go to PubMed...
  40. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003; 92: 152-160. Go to original source... Go to PubMed...
  41. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95: 120-122. Go to original source... Go to PubMed...
  42. Keech A, Simes RJ, Barter P, et al. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861. Go to original source... Go to PubMed...
  43. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001; 69: 340-345. Go to original source... Go to PubMed...
  44. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003; 73: 538-544. Go to original source... Go to PubMed...
  45. Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Non-high-density and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol 2006; 98: 1363-1368. Go to original source... Go to PubMed...
  46. Maccubbin D, Sirah W, Betteridge A, et al. Lipid-altering efficacy and tolerability profile of extended release niacin/ laropiprant in patients with primary hypercholesterolemia or mixed hyperlipidemia. Eur Heart J 2007; 28 (Suppl.): 108 (Abstract P715).
  47. Martin PD, Dane AL, Schneck DW, Warwick MJ. An openlabel, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003; 25: 459-471. Go to original source... Go to PubMed...
  48. McBride PE. Triglycerides and risk for coronary heart disease. JAMA 2007; 298: 336-338. Go to original source... Go to PubMed...
  49. McKenney JM, Farnier M, Lo KW et al. Safety and efficacy of long-term administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006; 47: 1584-1587. Go to original source... Go to PubMed...
  50. McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007; 192: 432-437. Go to original source... Go to PubMed...
  51. Miller M, Cannon CP, Ray K, et al. Impact of triglycerides in PROVE-IT TIMI-22: Does TG <150 improve CHD risk reduction beyond LDL <70. Circulation 2006; 114: 290.
  52. Nambi V, Ballantyne CM. Combination therapy with statins and omega-3 fatty acids. Am J Cardiol 2006; 98: 34I-38I. Go to original source... Go to PubMed...
  53. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 297: 299-308. Go to original source... Go to PubMed...
  54. Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/ NHLBI Clinical Advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 568-573. Go to original source... Go to PubMed...
  55. Penn R, Williams RX 3rd, Guha-Ray DK, Sawyers WG, Braun SL, Rains KT. An open-label, cross-over study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers. Clin Ther 2006; 28: 45-54. Go to original source... Go to PubMed...
  56. Prueksaritanont T, Tang C, Qui Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002; 30: 1290-1297. Go to original source... Go to PubMed...
  57. Rosolová H. Zásady farmakoterapie dyslipidemie u nemocných s diabetem 2. typu. Farmakoterapie 2007; 3 (2):185-189.
  58. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-418. Go to original source... Go to PubMed...
  59. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115: 450-458. Go to original source... Go to PubMed...
  60. Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006; 29: 1220-1226. Go to original source... Go to PubMed...
  61. Schnek DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004; 75: 455-63. Go to original source... Go to PubMed...
  62. Smith SC, Allen J, Blair SN et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006; 113: 236-272. Go to original source... Go to PubMed...
  63. St-Pierre AC, Cantin B, Dagenais GR et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005; 25: 553-559. Go to original source... Go to PubMed...
  64. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2. A double-blind, placebocontrolled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3512-3517. Go to original source... Go to PubMed...
  65. Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003; 107: 1733-1737. Go to original source... Go to PubMed...
  66. Vaverková H, Soška V. Co přinášejí nová doporučení pro diagnostiku a léčbu dyslipidémií. Interní Med. 2008; 10 (3): 117-120.
  67. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 2007; 369: 1090-1098. Go to original source... Go to PubMed...
  68. Zhao XQ, Yuan C, Hatsukami TS, et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol 2001; 21: 1623-1629. Go to original source... Go to PubMed...
  69. Žák A, Tvrzická E, Zeman M, Vecka M. Patofyziologie a klinický význam vícenenasycených mastných kyselin řady n-3. Čas. lék. čes. 2005; 144 (Suppl. 1): 6-18. Go to original source...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.